4.7 Article

Role of stromal activin A in human pancreatic cancer and metastasis in mice

期刊

SCIENTIFIC REPORTS
卷 11, 期 1, 页码 -

出版社

NATURE RESEARCH
DOI: 10.1038/s41598-021-87213-y

关键词

-

资金

  1. National Institutes of Health [R01 CA141057]

向作者/读者索取更多资源

The study reveals that high expression of Activin A in the stroma of PDAC patients is associated with poor prognosis, with pancreatic stellate cells (PSC) secreting Activin A to promote PDAC cell migration. Inhibition of Activin A in mice can decrease tumor metastases.
Pancreatic ductal adenocarcinoma (PDAC) has extensive stromal involvement and remains one of the cancers with the highest mortality rates. Activin A has been implicated in colon cancer and its stroma but its role in the stroma of PDAC has not been elucidated. Activin A expression in cancer and stroma was assessed in human PDAC tissue microarrays (TMA). Activin A expression in human TMA is significantly higher in cancer samples, with expression in stroma correlated with shorter survival. Cultured pancreatic stellate cells (PSC) were found to secrete high levels of activin A resulting in PDAC cell migration that is abolished by anti-activin A neutralizing antibody. KPC mice treated with anti-activin A neutralizing antibody were evaluated for tumors, lesions and metastases quantified by immunohistochemistry. KPC mice with increased tumor burden express high plasma activin A. Treating KPC mice with an activin A neutralizing antibody does not reduce primary tumor size but decreases tumor metastases. From these data we conclude that PDAC patients with high activin A expression in stroma have a worse prognosis. PSCs secrete activin A, promoting increased PDAC migration. Inhibition of activin A in mice decreased metastases. Hence, stroma-rich PDAC patients might benefit from activin A inhibition.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据